Comanche Biopharma
- Company typePrivate
- Founded2023
- HeadquartersConcord, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Comanche Biopharma firmographics
Firmographics- Name
- Comanche Biopharma
- Legal name
- Comanche Biopharma Corp.
- Website
- https://comanchebiopharma.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Comanche Biopharma industry classification
Industry- Product category
- Obstetric Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- siRNA Therapeutics (gene silencing) (HLAAADAB)
- akta.pro secondary industry
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where Comanche Biopharma is headquartered
LocationHeadquarters
- HQ city
- Concord
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Comanche Biopharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Pharmaceutical Drug Sales: Comanche Biopharma is a clinical-stage biopharmaceutical company developing CBP-4888, an investigational siRNA therapeutic for preeclampsia. The company does not yet have commercialized products and has no current revenue. Future revenue will come from sales of approved pharmaceutical products upon successful clinical development and regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Comanche Biopharma product offering
Product offeringCore offering
Comanche Biopharma is a clinical-stage biopharmaceutical company developing CBP-4888, an investigational siRNA therapeutic for preterm preeclampsia. CBP-4888 is a fixed-dose combination of two chemically synthesized, lipid-conjugated siRNA duplex oligonucleotides designed to selectively reduce overexpression of the sFlt-1 protein in the placenta. The drug is administered subcutaneously and is currently in Phase II clinical trials under FDA Fast Track, EMA Orphan Drug, and UK ILAP Innovation Passport designations.
Product overview
Comanche Biopharma is a clinical-stage biopharmaceutical company developing CBP-4888, an investigational siRNA therapeutic candidate for preterm preeclampsia. CBP-4888 is a fixed-dose combination of two lipid-conjugated siRNA duplex oligonucleotides designed to selectively downregulate sFlt1 protein overexpression in the placenta. The company is advancing this single drug candidate through global clinical trials, having received FDA Fast Track Designation, EMA Orphan Drug Designation, and UK Innovation Passport Designation.
Differentiator
Problem solved
Functional benefit
Brands
- CBP-4888: Novel siRNA drug candidate designed to selectively downregulate overexpression of the protein sFlt-1 (soluble fms-like tyrosine kinase-1) in the placenta for treating sFlt1-mediated preterm preeclampsia.
Products and services
- CBP-4888 A novel short-interfering RNA (siRNA) drug candidate designed to selectively reduce overexpression of the sFlt-1 (soluble fms-like tyrosine kinase-1) protein in the placenta, a key pathogenic driver of preeclampsia. It is a fixed-dose combination of two chemically synthesized, lipid-conjugated siRNA duplex oligonucleotides targeting two sFLT1 mRNA isoforms and is administered subcutaneously. The intended patients are pregnant women with sFlt1-mediated preterm preeclampsia, to be treated by obstetricians, maternal-fetal medicine specialists, and hospital systems.
Quantifiable outcome
- Expected to reduce sFlt1 protein levels in placenta, addressing root cause of preeclampsia
- +2 more outcomes
Companies that use Comanche Biopharma
Customer profileSegments2 records
Ideal customer profiles1 record
Comanche Biopharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Comanche Biopharma partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered supporting and core.
- Preeclampsia FoundationsupportingA non-profit organization that raises awareness and funds research for preeclampsia and other hypertensive disorders of pregnancy. Comanche is a proud supporter.
- EndPreeclampsiasupportingA patient advocacy organization that aims to increase awareness, education, and research about preeclampsia to improve the lives of women and babies affected by the condition. Founder Kara Boeldt serves on Comanche's Patient Advisory Board.
- Craig Mello (Scientific Advisor)coreNobel Laureate (2006) for discovery of RNA interference. Serves as Chair of Scientific Advisory Board. His foundational work on RNAi underpins Comanche's siRNA technology.
- Ananth Karumanchi (Scientific Advisor)coreDirector of Renovascular Research at Cedars-Sinai Medical Center. First identified the causal role of sFlt1 in preeclampsia. His discovery is the basis of the first diagnostic test for preeclampsia used in EU and UK standard of care.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Comanche Biopharma competitors and assessment
Company assessmentDirect peers
- Dicerna Pharmaceuticals (Novo Nordisk): Was a clinical-stage siRNA company (acquired by Novo Nordisk in 2021) developing GalXC™-conjugated siRNAs for rare and metabolic diseases. Closely comparable to Comanche on siRNA modality and conjugate chemistry, and exemplifies the typical exit path for clinical-stage siRNA companies.
- Alnylam Pharmaceuticals: The leading commercial-stage siRNA therapeutics company with multiple approved drugs (Onpattro, Givlaari, Oxlumo, Amvuttra, Leqvio). Directly comparable to Comanche on modality (siRNA) and lipid-conjugated delivery, and represents both a benchmark and a potential competitive threat in expanding siRNA indications.
- Arrowhead Pharmaceuticals: Clinical-stage siRNA therapeutics developer with a broad pipeline across pulmonary, liver, and muscle targets using TRiM™ and other conjugated platforms. Directly comparable on siRNA modality, lipid-conjugate delivery approach, and clinical-stage profile with multiple partnered programs.
- Silence Therapeutics: Clinical-stage siRNA company developing GalNAc-conjugated siRNAs for cardiovascular and rare diseases. Directly comparable on siRNA modality and lipid/GalNAc-conjugated chemistry, with a similar clinical-stage profile and platform focus.
Emerging players
- Wave Life Sciences: Clinical-stage RNA therapeutics company using PRISM™ platform for siRNA and antisense oligonucleotides. Comparable on RNA-based modality and clinical-stage development, though focused on neurological and rare-disease indications rather than maternal health.
- Sera Prognostics: Commercial-stage maternal-health diagnostics company with a preterm-blood test. Comparable to Comanche on indication (pregnancy complications) and biomarker-driven patient stratification, though focused on prediction rather than treatment.
- Mirvie: Emerging women's-health company developing a blood-based molecular diagnostic for early prediction of preeclampsia. Comparable to Comanche on indication focus (preeclampsia) and biomarker-driven approach, though operates in diagnostics rather than therapeutics.
Broad incumbents
- Ionis Pharmaceuticals: The leading antisense oligonucleotide (ASO) company with multiple approved drugs (Spinraza, Tegsedi, Waylivra) and a deep pipeline. Adjacent comparator on RNA-targeted therapeutic modality and rare-disease focus, though ASOs differ from siRNAs in mechanism and delivery.
- BridgeBio Pharma: Clinical-to-commercial-stage rare-disease biopharmaceutical company with multiple programs targeting genetically defined conditions. Comparable on rare-disease commercial strategy, orphan drug pathway experience, and clinical-stage development of single-mechanism therapeutics.
- Organon & Co. Global women's-health pharmaceutical company (spun off from Merck in 2021) with established maternal-health franchises. Comparable on target customer base (obstetricians, maternal-fetal medicine specialists) and commercial women's-health distribution, though not a direct competitor on a preeclampsia therapeutic.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Comanche Biopharma social profiles
Digital presenceComanche Biopharma compliance and trust
Trust signalCompliance4 records
Comanche Biopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Comanche Biopharma leadership team
Management profileNumber of profiles
Profiles6 records
Comanche Biopharma subsidiaries and ownership
Company hierarchySubsidiaries1 record
Comanche Biopharma funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Comanche Biopharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Comanche Biopharma
What does Comanche Biopharma do?
Comanche Biopharma is a clinical-stage biopharmaceutical company developing CBP-4888, an investigational siRNA therapeutic for preterm preeclampsia. CBP-4888 is a fixed-dose combination of two chemically synthesized, lipid-conjugated siRNA duplex oligonucleotides designed to selectively reduce overexpression of the sFlt-1 protein in the placenta. The drug is administered subcutaneously and is currently in Phase II clinical trials under FDA Fast Track, EMA Orphan Drug, and UK ILAP Innovation Passport designations.
Is Comanche Biopharma a public or private company?
Comanche Biopharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Comanche Biopharma founded?
Comanche Biopharma was founded in 2023. It employs 11 to 50 people.
Where is Comanche Biopharma based?
Comanche Biopharma is headquartered in Concord, United States, in the North America region.
How does Comanche Biopharma make money?
One revenue line is on record: pharmaceutical Drug Sales.
Who are Comanche Biopharma's main competitors?
Direct peers on record are Dicerna Pharmaceuticals (Novo Nordisk), Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals and Silence Therapeutics. Emerging players are Wave Life Sciences, Sera Prognostics and Mirvie. Broad incumbents are Ionis Pharmaceuticals, BridgeBio Pharma and Organon & Co..
Does Comanche Biopharma have an API?
No public API is recorded for Comanche Biopharma.
What industry is Comanche Biopharma in?
Comanche Biopharma's product category is Obstetric Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 541714 and its SIC code is 2834.